Equillium, Inc.
Equillium (Nasdaq: EQ) is a biotechnology company developing therapies for severe autoimmune and inflammatory disorders. Its preclinical pipeline includes EQ504, an aryl hydrocarbon receptor modulator initially being developed for ulcerative colitis and other gastrointestinal diseases, with potential applications in… From the company’s description.
In fiscal 2025, Equillium, Inc. reported a net loss of $22.40M. Operations used $22.75M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Equillium, Inc. does
In the company’s own words
Equillium (Nasdaq: EQ) is a biotechnology company developing therapies for severe autoimmune and inflammatory disorders. Its preclinical pipeline includes EQ504, an aryl hydrocarbon receptor modulator initially being developed for ulcerative colitis and other gastrointestinal diseases, with potential applications in inflammatory lung diseases, and EQ302, an orally delivered, selective inhibitor of IL-15 and IL-21 being evaluated for gastrointestinal conditions such as celiac disease. The company acquired EQ504 through its 2024 acquisition of Ariagen and EQ302 through its 2022 acquisition of Bioniz. Equillium has no commercial organization or manufacturing facilities; it relies on third-party contract manufacturers for product supplies and has not yet established sales or distribution capabilities. Its website is https://www.equilliumbio.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LA JOLLA, CA
- Fiscal year end
- December
- CIK
- 1746466
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Equillium, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Equillium, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Equillium, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Equillium, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Equillium, Inc.'s last four quarterly filings that the numbers alone won't show?”